Plasma Ceramides and Sphingomyelins in Relation to Heart Failure Risk.
ceramides
heart failure
sphingomyelins
Journal
Circulation. Heart failure
ISSN: 1941-3297
Titre abrégé: Circ Heart Fail
Pays: United States
ID NLM: 101479941
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
entrez:
13
7
2019
pubmed:
13
7
2019
medline:
25
4
2020
Statut:
ppublish
Résumé
Ceramides exhibit multiple biological activities that may influence the pathophysiology of heart failure. These activities may be influenced by the saturated fatty acid carried by the ceramide (Cer). However, the associations of different circulating Cer species, and their sphingomyelin (SM) precursors, with heart failure have received limited attention. We studied the associations of plasma Cer and SM species with incident heart failure in the Cardiovascular Health Study. We examined 8 species: Cer and SM with palmitic acid (Cer-16 and SM-16), species with arachidic acid (Cer-20 and SM-20), species with behenic acid (Cer-22 and SM-22), and species with lignoceric acid (Cer-24 and SM-24). During a median follow-up of 9.4 years, we identified 1179 cases of incident heart failure among 4249 study participants. In Cox regression analyses adjusted for risk factors, higher levels of Cer-16 and SM-16 were associated with higher risk of incident heart failure (hazard ratio for one SD increase:1.25 [95% CI, 1.16-1.36] and 1.28 [1.18-1.40], respectively). In contrast, higher levels of Cer-22 were associated with lower risk of heart failure in multivariable analyses further adjusted for Cer-16 (hazard ratio, 0.85 [0.78-0.92]); and higher levels of SM-20, SM-22 and SM-24 were associated with lower risk of heart failure in analyses further adjusted for SM-16 (hazard ratios, 0.83 [0.77-0.90], 0.81 [0.75-0.88], and 0.83 [0.77-0.90], respectively). No statistically significant interactions with age, sex, black race, body mass index, or baseline coronary heart disease were detected. Similar associations were observed for heart failure with preserved (n=529) or reduced (n=348) ejection fraction. This study shows associations of higher plasma levels of Cer-16 and SM-16 with increased risk of heart failure and higher levels of Cer-22, SM-20, SM-22, and SM-24 with decreased risk of heart failure. URL: https://www.clinicaltrials.gov . Unique identifier: NCT00005133.
Sections du résumé
BACKGROUND
Ceramides exhibit multiple biological activities that may influence the pathophysiology of heart failure. These activities may be influenced by the saturated fatty acid carried by the ceramide (Cer). However, the associations of different circulating Cer species, and their sphingomyelin (SM) precursors, with heart failure have received limited attention.
METHODS AND RESULTS
We studied the associations of plasma Cer and SM species with incident heart failure in the Cardiovascular Health Study. We examined 8 species: Cer and SM with palmitic acid (Cer-16 and SM-16), species with arachidic acid (Cer-20 and SM-20), species with behenic acid (Cer-22 and SM-22), and species with lignoceric acid (Cer-24 and SM-24). During a median follow-up of 9.4 years, we identified 1179 cases of incident heart failure among 4249 study participants. In Cox regression analyses adjusted for risk factors, higher levels of Cer-16 and SM-16 were associated with higher risk of incident heart failure (hazard ratio for one SD increase:1.25 [95% CI, 1.16-1.36] and 1.28 [1.18-1.40], respectively). In contrast, higher levels of Cer-22 were associated with lower risk of heart failure in multivariable analyses further adjusted for Cer-16 (hazard ratio, 0.85 [0.78-0.92]); and higher levels of SM-20, SM-22 and SM-24 were associated with lower risk of heart failure in analyses further adjusted for SM-16 (hazard ratios, 0.83 [0.77-0.90], 0.81 [0.75-0.88], and 0.83 [0.77-0.90], respectively). No statistically significant interactions with age, sex, black race, body mass index, or baseline coronary heart disease were detected. Similar associations were observed for heart failure with preserved (n=529) or reduced (n=348) ejection fraction.
CONCLUSIONS
This study shows associations of higher plasma levels of Cer-16 and SM-16 with increased risk of heart failure and higher levels of Cer-22, SM-20, SM-22, and SM-24 with decreased risk of heart failure.
CLINICAL TRIAL REGISTRATION
URL: https://www.clinicaltrials.gov . Unique identifier: NCT00005133.
Identifiants
pubmed: 31296099
doi: 10.1161/CIRCHEARTFAILURE.118.005708
pmc: PMC6629465
mid: NIHMS1531207
doi:
Substances chimiques
Ceramides
0
Eicosanoic Acids
0
Fatty Acids
0
Sphingomyelins
0
behenic acid
H390488X0A
arachidic acid
PQB8MJD4RB
lignoceric acid
RK3VCW5Y1L
Banques de données
ClinicalTrials.gov
['NCT00005133']
Types de publication
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e005708Subventions
Organisme : NHLBI NIH HHS
ID : U01 HL080295
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL130114
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268200800007C
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC55222
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC85086
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201200036C
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201800001C
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC85082
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC85083
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC85079
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG023629
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC85080
Pays : United States
Organisme : NHLBI NIH HHS
ID : N01HC85081
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL128575
Pays : United States
Références
Stat Methods Med Res. 1999 Mar;8(1):3-15
pubmed: 10347857
J Am Coll Cardiol. 2000 May;35(6):1628-37
pubmed: 10807470
Biochim Biophys Acta. 2002 Dec 30;1585(2-3):114-25
pubmed: 12531544
Am J Cardiol. 2004 Jan 15;93(2):234-7
pubmed: 14715358
Biochem Cell Biol. 2004 Feb;82(1):27-44
pubmed: 15052326
Cardiovasc Res. 2004 Aug 1;63(2):236-44
pubmed: 15249181
Heart Fail Rev. 2000 Jun;5(2):131-8
pubmed: 16228140
Am J Physiol Regul Integr Comp Physiol. 2006 Jan;290(1):R11-26
pubmed: 16352856
Prog Lipid Res. 2006 Jan;45(1):42-72
pubmed: 16445986
Circulation. 2006 Apr 25;113(16):1966-73
pubmed: 16618817
Ann Epidemiol. 1991 Feb;1(3):263-76
pubmed: 1669507
J Lipid Res. 2008 Oct;49(10):2101-12
pubmed: 18515784
Science. 2008 Oct 3;322(5898):110-5
pubmed: 18832646
Cardiovasc Res. 2009 May 1;82(2):175-83
pubmed: 19176603
Science. 2009 Apr 17;324(5925):343-4
pubmed: 19372418
Clin Exp Pharmacol Physiol. 2009 Nov;36(11):1054-61
pubmed: 19566828
FEBS Lett. 2010 May 3;584(9):1887-94
pubmed: 19857494
Chem Phys Lipids. 2011 Sep;164(6):590-606
pubmed: 21570958
Adv Exp Med Biol. 2011;721:19-39
pubmed: 21910080
Adv Exp Med Biol. 2011;721:41-56
pubmed: 21910081
Prog Lipid Res. 2012 Jan;51(1):50-62
pubmed: 22133871
J Biol Chem. 2012 May 25;287(22):18429-39
pubmed: 22493506
Cell Metab. 2012 May 2;15(5):585-94
pubmed: 22560211
JACC Heart Fail. 2014 Oct;2(5):477-88
pubmed: 24929535
J Lipid Res. 2015 Jan;56(1):176-84
pubmed: 25378659
Diabetes. 2018 Aug;67(8):1663-1672
pubmed: 29588286
J Am Heart Assoc. 2018 May 3;7(10):null
pubmed: 29728014
J Am Heart Assoc. 2018 Nov 6;7(21):e010019
pubmed: 30608197
Eur Heart J. 1993 Nov;14(11):1493-8
pubmed: 8299631
Am J Pathol. 1996 Jan;148(1):141-9
pubmed: 8546201
Circulation. 1997 Oct 7;96(7):2455-61
pubmed: 9337224
J Am Coll Cardiol. 1998 May;31(6):1352-6
pubmed: 9581732